BioPharma Adopting Adaptive Designs Earlier
Contribution by Phil Birch, Ph.D., Senior Vice President, Global Strategic Marketing at Aptiv Solutions
Adaptive designs can bring substantial benefits to sponsor companies if adopted broadly at the portfolio level. For instance, available data indicate that futility stopping in Phase II and Phase III can save mid-size biopharma companies between $5 million and $10 million in direct costs and $15 million to $35 million in indirect costs. For large biopharma companies, cost savings can be significantly larger depending on the size of the product portfolio: $20 million to $50 million for direct costs and $50 million $100 million for indirect costs.